Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 2b study, 834 adults with BMI ≥25 kg/m2 and type 2 diabetes inadequately controlled with metformin (glycated hemoglobin A1c [HbA1c] of 7.0%–10.5% [53–91 mmol/mol]) were randomized to double-blind cotadutide 100 μg (n = 100), 200 μg (n = 256), or 300 μg (n = 256); placebo (n = 110); or open-label liraglutide 1.8 mg (n = 110)—all administered subcutaneously. Coprimary end points were changes in HbA1c and body weight at week 14. The originally randomized interventions were continued to week 54. Liver damage biomarkers and liver fibrosis algorithms were assessed. RESULTS: Cotadutide significantly decreased HbA1c and body weight at weeks 14 and 54 versus placebo (all P < 0.001). Improvements in lipid profile, AST and ALT levels, propeptide of type III collagen level, fibrosis-4 index, and nonalcoholic fatty liver disease fibrosis score were observed with cotadutide 300 μg versus placebo, but not with liraglutide. Weight loss with cotadutide 200 μg was similar to that with liraglutide 1.8 mg and greater with cotadutide 300 μg versus liraglutide 1.8 mg. The most common adverse events with cotadutide (nausea, 35%; vomiting, 17%) decreased over time. CONCLUSIONS: Cotadutide treatment for 54 weeks improved glycemic control and weight loss in participants with overweight/obesity and type 2 diabetes. Ad hoc analyses demonstrated improvements in hepatic parameters and support further evaluation of cotadutide in NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cotadutide, but not liraglutide improved hepatic parameters and metabolic dysfunction-associated steatohepatitis (MASH) with similar weight loss with 200 μg cotadutide compared to 1.8 mg liraglutide and greater with 300 μg cotadutide versus 1.8 mg liraglutide [47].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“cotadutide did induce a dose-dependent 4–8 times greater reduction in triglycerides over liraglutide.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first GLP-1R/GCGR agonist to be put in clinical trials, cotadutide, produced comparable reductions in body weight and blood sugar levels in adults with overweight or obesity, and T2D as 1.8 mg of liraglutide [82].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Through a phase 2b trial, cotadutide 300 μg was shown to significantly improve liver injury enzymes, propeptide of type III collagen level, FIB-4, and NAFLD fibrosis score compared to placebo (but not compared to liraglutide) and reduce body weight more than treatment with liraglutide 1.8 mg.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [173]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from combining existing drugs, the development of dual GLP-1/glucagon receptor or GLP-1/GIP agonists or even triagonists237 with first promising results in NASH237–239 may show up another promising approach in drug development.”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [239]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“The pathology of NAFLD can progress further to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and end-stage cirrhosis (7).”
BackgroundByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042 · cited 1×
“Because the majority of deaths linked with NAFLD are attributable to cardiovascular disease, and given the close association between type 2 diabetes and NAFLD, therapeutic agents that improve both liver health and cardiometabolic risk are clinically valuable (36,37).”
BackgroundFox, C. S., Massaro, J. M., Hoffmann, U., Pou, K. M., Maurovich-Horvat, P., Liu, C.-Y., Vasan, R. S., Murabito, J. M., Meigs, J. B., Cupples, L. A., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.675355 · Cited by 2,882 · cited 1×
“Increased adipose tissue has been associated with increased cardiometabolic risk (43,44).”
BackgroundEinarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Increased adipose tissue has been associated with increased cardiometabolic risk (43,44).”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · cited 1×
“In previous studies of participants with obesity and NASH, weight loss achieved through lifestyle modifications decreased intrahepatic fat and ALT levels while improving hepatic fibrosis (32,33).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has been shown to improve glycemic control (13), delay gastric emptying, and induce weight loss in people with type 2 diabetes (14,15).”
BackgroundDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Cited by
Items 301–324 of 324
Doppi e tripli agonisti recettoriali nel trattamento del diabete mellito tipo 2
Pizzo, A., Paccagnella, M., Luca, F. D., & Candido, R. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01710-0 · Cited by 1
Ali, M. M., Hafez, A., Abdelgalil, M. S., Hasan, M. T., El-Ghannam, M. M., Ghogar, O. M., Elrashedy, A. A., & Abd‐ElGawad, M. (2022) · Figshare · doi:10.6084/m9.figshare.19686997
Winther‐Sørensen, M., Rasmussen, C. B., Trammell, S. A. J., Hansen, C., Vyberg, M., Serizawa, R., Richter, E. A., Grevengoed, T. J., Gluud, L. L., Kuhre, R. E., et al. (2025) · Peptides · doi:10.1016/j.peptides.2025.171462 · Cited by 2
Tailleux, A., & Kamel, S. (2026) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(26)76568-0
From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies
Yu, H., Ding, H., Huang, Y., Cao, H., Ding, Y., & Wang, W. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70036 · Cited by 1
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Current trends in pharmacotherapy of overweight and obesity
Ürgeová, A., & Kozárová, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.099
Njeim, R., Abureesh, O., Sohail, A., Tam, R., & Deeb, L. S. (2026) · Livers · doi:10.3390/livers6030035
“Subsequent phase 2b studies in patients with type 2 diabetes revealed significant reductions in liver transaminases (ALT, AST, GGT) and improvements in noninvasive fibrosis markers, including the NAFLD fibrosis score, FIB-4, and PRO-C3 levels [54,55].”
Zhou, L., Wu, P., Xu, Y., & Xie, B. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02697-2 · Cited by 2
Targeting Complexity:Scientific Foundation and Frontiers of Multi-target Drug Discovery
Zhu, K., Wen, X., & Sun, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025.08.05.0004
“…包括亲和力 、 溶解度 、 合成可行性等 多关键指标 [ 46 ] 。其主要应用方式包括 :( 1 ) 分子生成与 Deep-PK [ 47 ] ), 可以对吸收 ( A )、 分布 ( D )、 代谢 ( M )、 排泄 ( E ) 及毒性 ( T ) 五类成药性指标进行全面预测 , 提前排除不 具备开发潜力的化合物。 ( 3 ) 脱靶效应评估。通过利用 化学基因组数据 ( 如 PubChem BioAssay [ 48 ] ) 训练预测模 双拮抗剂 CP21 [ 50 ] 能够同时阻断 PD-L1 介导的 T 细胞耗 者中显示出良好疗效 [ 51 ] 。这类分子通常采用 “ 嵌合肽 ””
Fouad, Y. M., Abdelghany, W. A., & Sheemy, R. Y. E. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.118303
Hypogonadism and Metabolic Disorders
Cignarelli, A., Genchi, V. A., & Jayasena, C. N. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_50-1 · Cited by 1
Simental‐Mendía, L. E., Simental-Mendía, M. A., Aguillón-Marín, P., & Sánchez‐García, A. (2026) · Journal of Investigative Medicine · doi:10.1177/10815589261460894
Yang, Y., Zhang, F., Peng, Z., Wu, Y., Li, L., Shen, Z., Ye, Q., Yue, J., & Na, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.029
Ekinci, E. I., Maldonado, S. G., Unseld, A., Arrubla, J., Hennige, A. M., & Schoelch, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70861
“When hyperglycaemia is mitigated via concurrent GLP-1 receptor agonism, glucagon receptor activation can reduce adiposity and improve insulin sensitivity, thereby indirectly supporting beta-cell functional recovery while maintaining thermogenic and anorectic benefits [29, 56].”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.06.013
Role of glucagon in metabolic diseases
Kitamura, T., Tabei, Y., & Kobayashi, M. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70416
“Similarly, the glucagon/GLP-1 dual agonists cotadutide and mazdutide have demonstrated greater improvements in body weight and HbA1c than the GLP-1 receptor agonists liraglutide (1.8 mg) and dulaglutide (1.5 mg), respectively 14,15 .”
InfluentialIncretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
“Regarding dual GLP-1/glucagon RAs, cotadutide significantly reduced body weight, HbA1c, and hepatic fibrosis, as demonstrated by non-invasive biomarkers as well as biopsy findings in patients with obesity and T2D [42, 43].”
Dyslipidemia in cardio-reno-metabolic syndrome
Karásek, D. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.071
Cao, D., & Zhao, Z. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1018078
Argano, C., Maggio, D., Pollicino, C., Cangialosi, V., Manno, S. B., Orlando, V., Monti, M. L., Grutta, A., Torres, A., & Corrao, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1784959
“Compared with later-generation compounds, cotadutide reflects an early design strategy prioritising glycaemic stability and tolerability over maximal metabolic efficacy (Boland et al., 2020; Nahra et al., 2021).”
From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism
Saldívar-Cerón, H. I., Maldonado-Trejo, D., Chavez-Castañeda, Q., Mercado-Guzmán, A. L., León-Barrita, A. D. J., López-García, I. A., Hernández-Solís, A., Ramírez-Mendoza, A. M., Terrazas-Delgado, D. A., Castañeda-Ramírez, A. E., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219654 · Cited by 1
Metadata
- Authors
- Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P.
- Affiliations
- AstraZeneca (United States) (US)
- Pennington Biomedical Research Center (US)
- AstraZeneca (Sweden) (SE)
- 5Division of Endocrinology, University Hospital Leipzig, Leipzig, Germany
- AstraZeneca (United Kingdom) (GB)
- 4Clinical Metabolism, Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- Corresponding author
- Nahra, Rajaa
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-06-01
- Volume
- 44
- Issue
- 6
- Pages
- 1433-1442
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC8247525
- OpenAlex
- W3160773731
- Semantic Scholar
- 0019fb9a1c6044e014f9a7ae0dd18ea9907668eb
- Cited by
- 323
- References
- 47
- Citations by year
- 2026: 36 · 2025: 65 · 2024: 76 · 2023: 83 · 2022: 48 · 2021: 14
- FWCI
- 41.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-10-13)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, glucagon receptor agonist, type 2 diabetes, obesity, overweight, glycemic control, HbA1c, weight loss, non-alcoholic fatty liver disease, liver fibrosis, liver injury biomarkers, liraglutide, lipid profile, adverse events, nausea and vomiting, dose comparison
- MeSH terms
- Liraglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Liver, Obesity, Peptides, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.